Nephrocare Health Services has released the transcript of its investors' conference call regarding the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported a 32.2% increase in revenue to ₹998.8 crore for FY26, driven by a 16.6% growth in treatment volumes and a 13.3% rise in revenue per treatment. Adjusted PAT for the year surged 74.6% to ₹128.3 crore, reflecting strong operating leverage and margin expansion.

Financial Performance Overview

For the full fiscal year, revenue grew to ₹998.8 crore from ₹755.8 crore in FY25. Adjusted EBITDA increased 37.6% to ₹238.1 crore, with margins improving by 100 basis points to 23.8%. The company reported an annual pre-tax Return on Capital Employed (ROCE) of 22.8%, an improvement from 19.9% in the previous year. For Q4 FY26, revenue stood at ₹265.6 crore, a 21.2% year-on-year increase, while Adjusted PAT was ₹35 crore.

Key Financial Metrics

The following table summarises the key financial metrics for Q4 and FY26:

Operational and Strategic Highlights

Nephrocare Health Services recorded 38,44,658 dialysis sessions in FY26, a 16.6% increase over the previous year. The active guest count grew by 11.8% to 36,981. The international revenue contribution rose from 32% in FY25 to 42% in FY26, driven by expansions in the Philippines and Uzbekistan. The company continues to target a revenue CAGR of 15% to 20% over the next three to four years, supported by its asset-light model and disciplined capital allocation.

nephrocare health services has expanded its international footprint through its overseas step-down wholly-owned subsidiary, Nephrocare Health Care Services Philippines Inc. The subsidiary entered into two separate Asset Transfer Agreements (ATAs) to acquire identified assets pertaining to dialysis centers in the Philippines. The total consideration for these acquisitions amounts to PHP 72,200,000.00, approximately INR 11.24 Crores, strengthening the company's presence in the renal care market.

The first agreement was executed on May 26, 2026, with Northern Mindanao Dialysis Clinic Inc. (NMDCl). This ATA, dated May 22, 2026, covers the acquisition of assets for a dialysis center located at Cagayan De Oro City, Misamis Oriental. The transaction value for this center is PHP 27,400,000.00, which is approximately INR 4.25 Crores.

The second agreement was also executed on May 26, 2026, with Aliaga Hemodialysis Centre Inc. (Aliaga). This acquisition involves assets for a dialysis center situated at Brgy. Sto. Rosario, Aliaga, Nueva Ecija. The consideration for this center is PHP 44,800,000.00, approximately INR 6.99 Crores.

The disclosures confirm that the sellers in both transactions are not related to the promoter or promoter group of Nephrocare Health Services Limited. Consequently, these transactions do not fall under related party transactions and were conducted at arm's length. The agreements do not confer any special rights, such as the right to appoint directors or restrict changes in capital structure.

Details of Acquisition Agreements

The information was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kishore Kathri, Company Secretary & Compliance Officer, signed the disclosure on May 26, 2026.